2024
Rates, Predictors, and Outcomes of Ustekinumab Dose Escalation in Inflammatory Bowel Disease.
Petrov J, Al-Bawardy B, Alzahrani R, Mohamed G, Fine S. Rates, Predictors, and Outcomes of Ustekinumab Dose Escalation in Inflammatory Bowel Disease. Journal Of Clinical Gastroenterology 2024 PMID: 38595134, DOI: 10.1097/mcg.0000000000002003.Peer-Reviewed Original ResearchUstekinumab dose escalationDose-escalation groupInflammatory bowel diseaseDose escalationC-reactive proteinEndoscopic healingEscalation groupClinical remissionNormalization of C-reactive proteinSteroid-free clinical remissionBowel diseaseSerum C-reactive proteinNormalization of serum C-reactive proteinMaintenance of remissionReal-world cohortProportion of patientsUstekinumab doseMean hemoglobinBaseline albuminRetrospective studyUstekinumabMale sexMultivariate analysisPrimary outcomeSecondary outcomesImpact of COVID-19 Treatment on Real-World Outcomes in Inflammatory Bowel Disease
Sahyoun L, Fetene J, McMillan C, Protiva P, Al Bawardy B, Gaidos J, Proctor D. Impact of COVID-19 Treatment on Real-World Outcomes in Inflammatory Bowel Disease. Digestive Diseases And Sciences 2024, 69: 1654-1660. PMID: 38466459, DOI: 10.1007/s10620-024-08355-3.Peer-Reviewed Original ResearchSevere COVID-19 infectionInflammatory bowel diseaseCOVID-19 infectionIBD flareIBD therapyCOVID-19 treatmentSingle-center retrospective study of adult patientsMethodsA single-center retrospective studyAdvanced therapiesRetrospective study of adult patientsBowel diseaseStudy of adult patientsInflammatory bowel disease therapyDevelopment of severe COVID-19 infectionSevere COVID-19Acute COVID-19Corticosteroid useNo significant differenceNo therapyAdult patientsSupplemental oxygenPrimary outcomeSecondary outcomesTherapyCorticosteroidsEpstein-Barr virus seroprevalence among inflammatory bowel disease patients in Saudi Arabia
Al-Bawardy B, Alfadley A, Almousallam M, AlShathri S, Aboueissa M, Alsulaiman A, Attamimi M, AlMutairdi A. Epstein-Barr virus seroprevalence among inflammatory bowel disease patients in Saudi Arabia. Saudi Journal Of Gastroenterology 2024, 30: 168-172. PMID: 38358251, PMCID: PMC11198918, DOI: 10.4103/sjg.sjg_380_23.Peer-Reviewed Original ResearchSeroprevalence of EBVEpstein-Barr virusInflammatory bowel diseaseYears of ageEBV seroprevalenceEpstein-Barr virus statusCohort of IBD patientsDiagnosis of inflammatory bowel diseaseInflammatory bowel disease patientsRetrospective chart reviewFollow-up timeRate of seroconversionNon-exposureEBV seroconversionThiopurine therapyEBV-seropositiveNegative patientsTertiary centerIBD patientsPrimary outcomeSecondary outcomesBowel diseasePatientsVirus seroprevalenceDisease patientsUstekinumab Drug Levels and Outcomes in Inflammatory Bowel Disease.
Petrov J, Fine S, Alzahrani R, Mohamed G, Al-Bawardy B. Ustekinumab Drug Levels and Outcomes in Inflammatory Bowel Disease. Journal Of Clinical Gastroenterology 2024 PMID: 38300529, DOI: 10.1097/mcg.0000000000001978.Peer-Reviewed Original ResearchArea under the curveInflammatory bowel diseaseEndoscopic healingTrough levelsBowel diseaseAssociated with favorable outcomesUstekinumab trough levelsHighest area under the curveCohort of patientsTherapeutic drug monitoringClinical remissionCombination therapyMedian ageCRP normalizationRetrospective studyDrug levelsFavorable outcomeUstekinumabDrug monitoringPrimary outcomeSecondary outcomesCRPPatientsOutcomesHealing
2023
Early Flexible Sigmoidoscopy Improves Clinical Outcomes in Acute Severe Ulcerative Colitis
Sharma S, Li D, Levine L, Chaar A, McMillan C, Gaidos J, Proctor D, Al-Bawardy B. Early Flexible Sigmoidoscopy Improves Clinical Outcomes in Acute Severe Ulcerative Colitis. Crohn's & Colitis 360 2023, 5: otad032. PMID: 37323477, PMCID: PMC10263117, DOI: 10.1093/crocol/otad032.Peer-Reviewed Original ResearchAcute severe ulcerative colitisSevere ulcerative colitisClinical outcomesSigmoidoscopy groupHospital stayFlexible sigmoidoscopyUlcerative colitisIntravenous corticosteroid useRate of colectomyRisk of colectomyHours of admissionOpioid medication useShorter hospital stayCohort of patientsFavorable clinical outcomeLarge prospective studiesRelevant clinical outcomesColectomy rateCorticosteroid useSecondary outcomesMedication usePrimary outcomeProspective studyRetrospective studySigmoidoscopyOutcomes of immunomodulator and advanced therapies for primary sclerosing cholangitis-associated inflammatory bowel disease
Sayed A, Assis D, Silveira M, Deng Y, Ciarleglio M, Gaidos J, Proctor D, Al-Bawardy B. Outcomes of immunomodulator and advanced therapies for primary sclerosing cholangitis-associated inflammatory bowel disease. European Journal Of Gastroenterology & Hepatology 2023, 35: 270-274. PMID: 36708297, DOI: 10.1097/meg.0000000000002510.Peer-Reviewed Original ResearchConceptsPrimary sclerosing cholangitisInflammatory bowel diseasePSC-IBDEndoscopic healingTherapy groupAdvanced therapiesClinical remissionBowel diseaseAcute ascending cholangitisRate of cholangitisSmall bowel involvementThird of patientsAscending cholangitisSclerosing cholangitisAdult patientsBowel involvementSecondary outcomesMedian agePrimary outcomeRetrospective studyHigh riskCholangitisPatientsTherapyLarger study
2022
Effect of obesity on vedolizumab response in inflammatory bowel disease
Levine LJ, Gaidos JKJ, Proctor DD, Viana AV, Al-Bawardy B. Effect of obesity on vedolizumab response in inflammatory bowel disease. Annals Of Gastroenterology 2022, 35: 275-280. PMID: 35599926, PMCID: PMC9062841, DOI: 10.20524/aog.2022.0699.Peer-Reviewed Original ResearchBody mass indexInflammatory bowel diseaseSteroid-free clinical remissionNon-obese groupC-reactive proteinObese groupCRP normalizationEndoscopic remissionIBD patientsBowel diseaseDose escalationNormal serum C-reactive proteinMedian body mass indexSerum C-reactive proteinHigher body mass indexEndoscopic remission ratesEffect of obesityVedolizumab discontinuationVedolizumab levelsClinical remissionMedian followRemission rateSecondary outcomesMedian agePrimary outcomeImpact of thiopurine dose in anti-tumor necrosis factor combination therapy on outcomes in inflammatory bowel disease
Nawaz A, Glick L, Chaar A, Li D, Gaidos J, Proctor D, Al-Bawardy B. Impact of thiopurine dose in anti-tumor necrosis factor combination therapy on outcomes in inflammatory bowel disease. Annals Of Gastroenterology 2022, 36: 39-44. PMID: 36593807, PMCID: PMC9756033, DOI: 10.20524/aog.2022.0766.Peer-Reviewed Original ResearchInflammatory bowel diseaseC-reactive proteinAnti-TNF combination therapySteroid-free clinical remissionCombination therapyThiopurine doseDose groupEndoscopic healingClinical remissionBowel diseaseUlcerative colitisCrohn's diseaseTherapeutic doseNormal serum C-reactive proteinAnti-tumor necrosis factorNormal C-reactive proteinSerum C-reactive proteinAnti-drug antibody formationAnti-TNF immunogenicityCohort of patientsLow-dose groupSignificant differencesSecondary outcomesPrimary outcomeClinical outcomes
2020
The Impact of Vedolizumab on Pre-Existing Extraintestinal Manifestations of Inflammatory Bowel Disease: A Multicenter Study
Ramos GP, Dimopoulos C, McDonald NM, Janssens LP, Hung KW, Proctor D, Ruggiero E, Kane S, Bruining DH, Faubion WA, Raffals LE, Loftus EV, Al-Bawardy B. The Impact of Vedolizumab on Pre-Existing Extraintestinal Manifestations of Inflammatory Bowel Disease: A Multicenter Study. Inflammatory Bowel Diseases 2020, 27: 1270-1276. PMID: 33165569, DOI: 10.1093/ibd/izaa293.Peer-Reviewed Original ResearchConceptsInflammatory bowel diseaseExtraintestinal manifestationsPeripheral arthritisBowel diseaseDose of vedolizumabPrevious biologic useMulticenter retrospective studyCurrent medical therapyTerms of ageConcurrent immunosuppressantsCorticosteroid therapyVDZ treatmentIBD subtypesBiologic useSecondary outcomesMedical therapyPrimary outcomeClinical outcomesMulticenter studyRetrospective studyVedolizumabPatientsCommon typeDiscontinuationArthritis
2018
Outcomes of repeat balloon assisted enteroscopy in small-bowel bleeding
Al-Bawardy B, Ramos G, Lennon R, Gorospe E, Song L, Bruining D, Alexander J, Coelho-Prabhu N, Fidler J, Rajan E. Outcomes of repeat balloon assisted enteroscopy in small-bowel bleeding. Endoscopy International Open 2018, 06: e694-e699. PMID: 29868634, PMCID: PMC5979197, DOI: 10.1055/a-0599-6085.Peer-Reviewed Original ResearchSmall bowel bleedingTherapeutic yieldAdverse eventsAntegrade routeOnly significant predictive factorChronic obstructive pulmonary diseaseSelf-limited abdominal painChronic kidney diseaseAdverse event ratesObstructive pulmonary diseaseSignificant predictive factorsCardiac comorbiditiesRepeat balloonAbdominal painSecondary outcomesPrimary outcomePulmonary diseaseRetrospective reviewPredictive factorsKidney diseaseBACKGROUND/Diagnostic yieldNegative groupMultivariate analysisEvent rates